MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
20.34
-0.80
-3.78%
After Hours: 20.35 +0.01 +0.05% 19:51 12/18 EST
OPEN
21.15
PREV CLOSE
21.14
HIGH
21.64
LOW
20.14
VOLUME
2.38M
TURNOVER
--
52 WEEK HIGH
129.84
52 WEEK LOW
10.42
MARKET CAP
2.13B
P/E (TTM)
-6.3810
1D
5D
1M
3M
1Y
5Y
1D
Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)
TipRanks · 15h ago
Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Risk‑Reward Narrative?
Simply Wall St · 17h ago
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
Seeking Alpha · 1d ago
Assessing Sarepta Therapeutics (SRPT) Valuation After a Recent Share Price Rebound
Simply Wall St · 1d ago
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings
Seeking Alpha · 2d ago
HHS adds Duchenne muscular dystrophy to recommended screening panel
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Argenx Se (ARGX) and Sarepta Therapeutics (SRPT)
TipRanks · 2d ago
Weekly Report: what happened at SRPT last week (1208-1212)?
Weekly Report · 3d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.